 |
市場調查報告書
商品編碼
2075762
搔癢症治療市場：依療法分類、適應症、給藥途徑及地區分類Pruritus Therapeutics Market, By Therapeutic Class, By Indication, By Route of Administration, By Geography |
||||||
價格
簡介目錄
預計到 2026 年，搔癢症治療市場規模將達到 36 億美元，到 2033 年將達到 78 億美元。預計從 2026 年到 2033 年，該市場將以 11.4% 的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 36億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 11.40% | 2033年市場規模預測： | 78億美元 |
全球搔癢治療市場涵蓋生物製藥、小分子抑制劑和外用製劑等多種治療類別，主要針對慢性腎臟病相關搔癢（CKD-aP）、異位性皮膚炎和乾癬等疾病。這些產品劑型多樣，包括注射、口服藥物和外用製劑，有助於提高療效、效能和可靠性。這些領域應用範圍的不斷擴大以及持續的產品創新，將繼續推動市場成長。
市場動態：
預計推動全球搔癢治療市場成長的主要因素包括：關鍵應用領域需求的成長、對療效和性能日益重視以及持續的產品創新。注射劑和口服製劑的廣泛應用，以及對先進解決方案投資的增加，也將進一步促進市場擴張。
例如，各公司正日益開發針對慢性腎臟病相關搔癢（CKD-aP）及相關應用的客製化產品。此外，持續的研發投入和新技術的整合預計將在預測期內為市場參與者創造新的成長機會。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據公司概況、產品系列、主要亮點、財務表現和策略等參數，介紹了全球搔癢治療市場主要公司的概況。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球搔癢症治療市場報告」旨在為該行業的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 透過對全球搔癢症治療市場進行分析時所使用的各種策略矩陣，相關人員將能夠做出更順利的決策。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場概覽
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期產品發布
- 流行病學
- 併購和合作
- 監管趨勢
- 主要進展
- PEST分析
- 夥伴關係方案
- 品牌和定價分析
- 銷售代理情況
- 波特的分析
- 技術進步
- 主要進展
- 市場趨勢
- 前景
- 按銷售收入排名的主要公司
第4章：搔癢症治療市場：依治療類別分類，2026-2033年
- 生物製劑
- 小分子抑制劑
- 外用製劑
- 全身性皮質類固醇
- 其他
第5章：搔癢症治療市場：依適應症分類，2026-2033年
- 慢性腎臟病相關搔癢症 (CKD-aP)
- 異位性皮膚炎
- 銀屑病
- 膽汁淤積性搔癢
- 其他皮膚病
第6章：搔癢症治療市場：依給藥途徑分類，2026-2033年
- 注射藥物
- 口服
- 外用
- 其他
第7章：搔癢症治療市場：依地區分類，2026-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 比荷盧經濟聯盟
- 丹麥
- 挪威
- 瑞典
- 其他歐洲國家
- 亞太地區
- 中國
- 台灣
- 印度
- 日本
- 印尼
- 馬來西亞
- 菲律賓
- 新加坡
- 澳洲
- 韓國
- 其他亞太國家
- 中東和非洲
- 巴林
- 科威特
- 阿曼
- 卡達
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 北非
- 中非
- 其他中東國家
第1章 競爭情勢
- Horizon Therapeutics plc
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi SA
- Novartis AG
- Astellas Pharma Inc.
- AbbVie Inc.
- GlaxoSmithKline plc
- UCB SA
- Eli Lilly and Company
- Sun Pharmaceutical Industries Ltd.
- Johnson & Johnson
- Amgen Inc.
- Mundipharma International Limited
- F. Hoffmann-La Roche Ltd.
- Kyowa Kirin Co.Ltd.
第1章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI4492
Pruritus Therapeutics Market is estimated to be valued at USD 3.6 billion in 2026 and is expected to reach USD 7.8 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.6 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.40% | 2033 Value Projection: | USD 7.8 billion |
The global pruritus therapeutics market comprises therapeutic class categories such as Biologics, Small Molecule Inhibitors, and Topical Agents, serving applications including Chronic Kidney Disease-Associated Pruritus(CKD-aP), Atopic Dermatitis, and Psoriasis. These offerings are adopted across Injectable, Oral, and Topical and other areas, where they support improved efficiency, performance, and reliability. Growing adoption across these segments, combined with ongoing product innovation, continues to support expansion of the market.
Market Dynamics:
Rising demand across key application areas, increasing emphasis on efficiency and performance, and continued product innovation are major factors expected to drive growth of the global pruritus therapeutics market. Expanding adoption among Injectable, and Oral and growing investment in advanced solutions are further supporting market expansion.
For instance, providers are increasingly developing offerings tailored to Chronic Kidney Disease-Associated Pruritus(CKD-aP) and related applications. Moreover, ongoing research and development, along with the integration of new technologies, is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global pruritus therapeutics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Horizon Therapeutics plc, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Novartis AG, Astellas Pharma Inc., AbbVie Inc., GlaxoSmithKline plc, UCB S.A., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Johnson & Johnson, Amgen Inc., Mundipharma International Limited, F. Hoffmann-La Roche Ltd., and Kyowa Kirin Co.Ltd. Bottom of Form, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global pruritus therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pruritus therapeutics market.
Detailed Segmentation:
- Global Pruritus Therapeutics Market, By Therapeutic Class (Revenue, USD Bn, 2021 - 2033)
- Biologics
- Small Molecule Inhibitors
- Topical Agents
- Systemic Corticosteroids
- Others
- Global Pruritus Therapeutics Market, By Indication (Revenue, USD Bn, 2021 - 2033)
- Chronic Kidney Disease-Associated Pruritus(CKD-aP)
- Atopic Dermatitis
- Psoriasis
- Cholestatic Pruritus
- OtherDermatological Conditions
- Global Pruritus Therapeutics Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Injectable
- Oral
- Topical
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Horizon Therapeutics plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sanofi S.A.
- Novartis AG
- Astellas Pharma Inc.
- AbbVie Inc.
- GlaxoSmithKline plc
- UCB S.A.
- Eli Lilly and Company
- Sun Pharmaceutical Industries Ltd.
- Johnson & Johnson
- Amgen Inc.
- Mundipharma International Limited
- F. Hoffmann-La Roche Ltd.
- Kyowa Kirin Co.Ltd. Bottom of Form
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapeutic Class
- Market Snapshot, By Indication
- Market Snapshot, By Route of Administration
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Pruritus Therapeutics Market By Therapeutic Class, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Small Molecule Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Topical Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Systemic Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Pruritus Therapeutics Market By Indication, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Chronic Kidney Disease-Associated Pruritus (CKD-aP)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Atopic Dermatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Cholestatic Pruritus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others Dermatological Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Pruritus Therapeutics Market By Route of Administration, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Pruritus Therapeutics Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, en2026-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Horizon Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- UCB S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mundipharma International Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kyowa Kirin Co.Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
1. Section
- Research Methodology
- About Us
